US Corporate Distress Financial Stress SEC Filings — March 31, 2026

31-03-2026

Prologis, L.P. entered into a Second Amended and Restated Global Senior Credit Agreement on March 26, 2026, with Bank of America, N.A. as Global Administrative Agent and a syndicate of lenders including ING Bank N.V., JPMorgan Chase Bank, N.A., and others, establishing U.S. and Euro committed loans, letters of credit, swing line facilities, and bid loans. The agreement includes provisions for global impact and sustainability, with CUSIPs assigned for the deal (74340YBP3), U.S. tranche (74340YBQ1), and Euro tranche (74340YBR9). No specific commitment amounts or financial metrics are detailed in the provided filing excerpt.

• ·Filing date: March 31, 2026
• ·Items reported: 1.01 (Entry into Material Definitive Agreement), 2.03 (Creation of a Direct Financial Obligation), 9.01 (Financial Statements and Exhibits)
• ·Deal CUSIP: 74340YBP3; U.S. Tranche CUSIP: 74340YBQ1; Euro Tranche CUSIP: 74340YBR9

31-03-2026

Ares Holdings L.P., a key subsidiary of Ares Management Corp, entered into a new Credit Agreement dated March 27, 2026, establishing a U.S. Dollar three-year delayed draw term loan facility with Bank of America, N.A. as administrative agent and BOFA Securities, Inc. as sole lead arranger and bookrunner. The agreement includes standard representations, covenants, and definitions such as Adjusted EBITDA with restrictions on fee inclusions (no more than 15% from Designated Subsidiaries or 5% from Unrestricted Subsidiaries), but no specific commitment amounts or draw details are provided in the filing excerpt.

• ·Applicable Margin for Term SOFR Rate Loans ranges from 0.750% (Level I) to 1.250% (Level V) based on Ares Parent’s senior long-term unsecured debt ratings from S&P/Fitch/Moody’s.
• ·Agreement filed as Exhibit 10.1 in 8-K on March 31, 2026 under Items 1.01, 2.03, 9.01.

31-03-2026

On March 30, 2026, Satellogic Inc. entered into a Sales Agreement with Cantor Fitzgerald & Co., Craig-Hallum Capital Group LLC, Northland Securities, Inc., and Roth Capital Partners, LLC, enabling the company to offer and sell up to $50,000,000 of its Class A common stock through an at-the-market offering. The Sales Agents will use commercially reasonable efforts to sell shares based on the company's instructions, with the company providing customary indemnification and reimbursements. A prospectus supplement was filed on the same day under the company's Form S-3 registration statement (File No. 333-294446).

• ·Registration statement on Form S-3 (File No. 333-294446) initially filed March 19, 2026; base prospectus dated March 27, 2026.
• ·Securities registered: Class A Common Stock (SATL) and Warrants (SATLW) on Nasdaq Capital Market.
• ·Legal opinion on share issuance provided by King & Spalding LLP (Exhibit 5.1).

31-03-2026

Red Cat Holdings, Inc. entered into a Share Purchase Agreement on March 30, 2026, to acquire all issued and outstanding capital stock of Quaze Technologies, Inc. through its wholly-owned subsidiary 9563-4747 Quebec Inc. for approximately $25,000,000 in shares of Company common stock, subject to adjustments for indebtedness, transaction expenses, and net working capital. Additional earnout consideration of up to $5,000,000 in shares is payable upon achieving certain integration, revenue, and gross margin thresholds.

• ·Acquisition closing subject to customary conditions including regulatory approvals, accuracy of representations and warranties, and continued Nasdaq listing of RCAT common stock.
• ·Purchase Agreement terminable if closing conditions not met by December 31, 2026.

31-03-2026

BMO Commercial Mortgage Securities LLC, as Depositor, executed a Pooling and Servicing Agreement dated as of March 1, 2026, for the BMO 2026-5C14 Mortgage Trust, establishing the framework for Commercial Mortgage Pass-Through Certificates, Series 2026-5C14, including conveyance of mortgage loans, servicing duties, and distributions to certificateholders. Key service providers include Midland Loan Services, a division of PNC Bank, N.A. (Master Servicer), CWCapital Asset Management LLC (Special Servicer), Pentalpha Surveillance LLC (Operating Advisor and Asset Representations Reviewer), and Computershare Trust Company, N.A. (Certificate Administrator and Trustee). The agreement details administrative, servicing, and compliance provisions with no specific financial performance metrics or period-over-period comparisons disclosed.

• ·No Class S Certificates, Class VRR Certificates, or Loan-Specific Certificates will be issued under this Agreement
• ·Agreement filed as Exhibit 99.1 in 8-K on March 31, 2026

31-03-2026

Ellington Credit Company entered into an indenture with Wilmington Trust, National Association for a public offering of $50 million aggregate principal amount of 8.50% Notes due 2031, with underwriters holding an option to purchase up to an additional $7.5 million within 30 days. The Notes, issued in $25 denominations, bear interest at 8.50% per year payable quarterly starting June 30, 2026, mature on March 30, 2031, and are expected to trade on the NYSE under 'ELLA'. They rank as general unsecured senior obligations, redeemable at 100% principal plus accrued interest on or after March 30, 2028.

• ·Notes issued in denominations of $25 and integral multiples thereof
• ·Redeemable in whole or in part on or after March 30, 2028, at 100% of principal plus accrued interest
• ·Indenture includes covenant to comply with 1940 Act asset coverage requirements
• ·Trading expected to commence within 30 days of original issue date

31-03-2026

Allbirds, Inc. (BIRD) entered a definitive asset purchase agreement with American Exchange Group (AXNY) to sell all intellectual property and certain assets/liabilities for an estimated $39 million, subject to shareholder approval via proxy statement by April 24, 2026, with closing expected in Q2 2026 followed by dissolution and net proceeds distribution in Q3 2026. The company cancelled its Q4 and FY 2025 earnings call scheduled for March 31, 2026, and plans to file its 10-K for the year ended December 31, 2025 on that date. While CEO Joe Vernachio highlighted the brand's legacy and future potential under AXNY, the transaction signals the end of Allbirds as an operating entity.

• ·Proxy statement expected no later than April 24, 2026
• ·Transaction close anticipated in Q2 2026
• ·Stockholder distribution of net proceeds (after wind-down expenses) anticipated in Q3 2026
• ·TD Cowen acting as financial advisor; Holland & Hart LLP as legal counsel to Allbirds
• ·Annual Report on Form 10-K for year ended December 31, 2025 to be filed March 31, 2026

31-03-2026

Lipella Pharmaceuticals Inc. and certain subsidiaries filed voluntary petitions for Chapter 11 bankruptcy relief in the United States Bankruptcy Court for the Western District of Pennsylvania on March 30, 2026. The filing warns that trading in the company's common stock during the Chapter 11 proceedings is highly speculative and carries substantial risks, with stock prices potentially unrelated to any shareholder recovery.

• ·Registrant is an emerging growth company.
• ·No securities registered pursuant to Section 12(b) of the Act.
• ·Exhibit 99.1: Press Release dated March 30, 2026.

31-03-2026

SCYNEXIS, Inc. announced a $40.0 million private placement of common shares, pre-funded warrants, and common warrants, with potential additional gross proceeds of up to $52.2 million upon full exercise of common warrants subject to stockholder approval. The net proceeds, combined with existing cash, are expected to fund operations into mid-2029. The transaction includes participation from institutional investors and CEO Dr. David Angulo, who purchased 108,695 shares.

• ·Closing expected on or about April 1, 2026, subject to customary conditions
• ·Common Warrants exercisable at $1.20 per share after Stockholder Approval
• ·Common Warrants expire on the earlier of fifth anniversary of closing or 30 days after Week 48 topline data release from SCY-770 Phase 2 study
• ·Stockholder meeting to approve authorized share increase no later than 90 days after closing
• ·Common Shares and warrants sold at $0.92 combined price; Pre-Funded at $0.9199

31-03-2026

Iterum Therapeutics plc received final notification on March 30, 2026, that its ordinary shares (ITRM) will be delisted from Nasdaq due to failure to maintain a $1.00 minimum bid price, following withdrawal of its appeal amid a filed winding up petition in Ireland's High Court on March 27, 2026. Trading will be suspended at the opening of business on April 1, 2026, with a Form 25-NSE to be filed to remove the shares from listing. Under joint provisional liquidators Damien Murran and Jennifer McMahon of Teneo Restructuring (Ireland) Limited, the company cites limited cash resources and does not expect to file its Form 10-K for FY ended December 31, 2025, or any future SEC reports.

• ·Prior delisting determination letter received February 24, 2026.
• ·Hearing request filed with Nasdaq Panel on March 3, 2026, which stayed suspension pending hearing.
• ·Winding up petition filed in Ireland High Court on March 27, 2026.

31-03-2026

On March 26, 2026, Willis Warehouse Facility LLC, a wholly-owned subsidiary of Willis Lease Finance Corporation (WLFC), entered into a Credit Agreement Termination Agreement to terminate a prior credit agreement dated May 3, 2024, involving Bank of America as facility agent and Bank of Utah as administrative agent and security trustee. No financial terms, impacts, or reasons for termination are disclosed in this filing. The full text of the termination agreement will be included as an exhibit in WLFC's upcoming 10-Q for the period ended March 31, 2026.

• ·Filing made pursuant to Items 1.02 (Termination of a Material Definitive Agreement) and 9.01 (Exhibits).
• ·Date of earliest event reported: March 26, 2026.
• ·Securities: Common Stock, $0.01 par value per share (WLFC) on Nasdaq Global Market.

31-03-2026

Repay Holdings Corporation (RPAY) announced a definitive agreement to acquire KUBRA for approximately $372 million in cash, financed by cash on hand and debt, creating a combined entity with projected 2025 revenue of $548 million and Adjusted EBITDA of $178 million, alongside over $130 billion in annual payment volumes. The deal is expected to deliver $15+ million in annual run-rate cost synergies, $5+ million in technology savings over three years, and 25% Free Cash Flow accretion by 2028, while expanding into utilities, government, and insurance verticals serving 250 clients and 40% of US/Canada households. The transaction anticipates closing in Q2 2026, subject to regulatory approvals, with expected net leverage of 4.0x at close reducing below 3.0x within 18 months.

• ·KUBRA founded in 1992, headquartered in Mississauga, Ontario
• ·Conference call scheduled for March 31, 2026 at 8:00 AM ET
• ·Transaction subject to US and Canada regulatory approvals and customary closing conditions
• ·Advisors: Truist Securities (financial to REPAY), Troutman Pepper Locke (legal to REPAY), Financial Technology Partners (financial to KUBRA), Clifford Chance US LLP and Hearst Office of General Counsel (legal to KUBRA)

31-03-2026

Classover Holdings, Inc. received a Nasdaq notice on November 21, 2025, stating that its Class B Common Stock (KIDZ) bid price had been below the $1.00 minimum for 30 consecutive business days, with 180 calendar days until May 20, 2026, to regain compliance. On March 26, 2026, Nasdaq confirmed the company regained compliance, as the bid price was at or above $1.00 for 12 consecutive business days. The company issued a press release on March 31, 2026, announcing this positive development.

• ·Filing intended to satisfy obligations under Items 3.01 (Notice of Delisting or Failure to Satisfy Listing Rule), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits).
• ·Company qualifies as an emerging growth company.
• ·Principal executive offices: 450 7th Avenue, Suite 905, New York, NY 10123.
• ·Press release included as Exhibit 99.1.

31-03-2026

Alerus Financial Corporation entered into a Modification Agreement dated March 30, 2026, with the Bank of North Dakota to amend its Subordinated Note originally issued in 2021 for $50,000,000 principal, which remains outstanding along with $1,769,444.44 in accrued interest and fees for a total of $51,769,444.44. Key changes include extending the maturity date to March 30, 2036, setting a fixed interest rate of 6.75% until March 30, 2031 followed by a variable rate, and allowing prepayments without penalty starting March 30, 2031. The agreement also updates various covenants referencing no material adverse changes since December 31, 2025, and adds requirements for insurance and Bank Subsidiary financial condition monitoring.

• ·Prepayment permitted on or after March 30, 2031 with five business days' notice, in minimums of $500,000 or integral multiples of $100,000, without penalty.
• ·No prepayment allowed before March 30, 2031 except in cases of Tier 2 Capital disqualification, Tax Event, or Investment Company Act registration requirement.
• ·New covenant requires Borrower and subsidiaries to maintain customary insurance, with evidence provided to Lender.
• ·Bank Subsidiary must report if leverage ratio <8.25%, total risk-based capital <10.50%, Texas Ratio >25%, or loans/assets >85%, potentially requiring executive summary.

31-03-2026

nCino reported record Q4 FY2026 total revenues of $149.7 million, up 6% YoY from $141.4 million, and FY2026 total revenues of $594.8 million, up 10% YoY from $540.7 million, with subscription revenues growing 7% to $133.4 million in Q4 and 12% to $523.1 million for the year. The company turned GAAP profitable with Q4 net income of $8.3 million (from -$18.6 million loss) and FY net income of $5.2 million (from -$37.9 million loss), while ACV reached $602.4 million, up 17% YoY (13% organic). Cash and equivalents declined to $88.7 million from $120.9 million prior year, with revolving credit facility outstanding at $213.5 million, amid announcement of a $100 million accelerated share repurchase funded by a $200 million term loan expansion.

• ·Q1 FY2027 guidance: Total revenues $154.5M-$156.5M; Subscription revenues $137.0M-$139.0M; Non-GAAP operating income $38.0M-$40.0M.
• ·FY2027 guidance: Total revenues $639.0M-$643.0M; Subscription revenues $569.0M-$573.0M; Non-GAAP operating income $165.0M-$170.0M; Free Cash Flow $132.0M-$137.0M; ACV $662.5M-$667.5M.
• ·New customer wins: Global bank with $2.0T assets in Japan for Commercial Lending; Expansion with $200B AUM bank; Top-40 U.S. bank for Mortgage; Top-3 Austrian bank for SME and Corporate Lending.

31-03-2026

iPower Inc. amended a $2.3 million promissory note from ETTS AI Investment LLC, stemming from the February 1, 2026 sale of its subsidiary Global Product Marketing, Inc. (GPM). The March 26, 2026 amendment expands the 'Change of Control' definition to include material changes in executive management/board composition, business model/core operations, or supply chain disposition, triggering automatic voiding of the note. While maintaining all other terms, this provides broader protections to ETTS AI, potentially increasing repayment risk for iPower with no offsetting benefits disclosed.

• ·Original agreements dated February 1, 2026: software asset transfer to GPM and stock purchase by ETTS AI.
• ·Amendment filed as Exhibit 10.1; only Section 8 amended, all other note terms unchanged.

31-03-2026

Mag Magna Corp., a rare earth elements mining company, entered into Lock-Up and Leak-Out Agreements effective March 27, 2026, with 11 consultants covering 8,900,000 shares (89% of 10,000,000 shares issued under its 2026 Stock Incentive Plan and S-8 Registration Statement). The agreements prohibit sales through December 31, 2026 (lock-up period), followed by a leak-out period through June 30, 2027, with monthly limits of 100,000 shares and daily limits of 20,000 shares, intended to promote stock price stability. Early termination is possible if the stock trades above $5.00 for 10 consecutive days post-lock-up.

• ·Lock-up Period ends December 31, 2026; Leak-out Period from January 1 to June 30, 2027
• ·Agreements include mutual release of claims and apply to transferees
• ·Board may discretionarily reduce, remove, or waive resale restrictions
• ·Company acquired first mining properties in January 2026

31-03-2026

On March 25, 2026, Texas Critical Data Centers LLC (TCDC), a wholly owned subsidiary of New Era Energy & Digital, Inc., entered into amendments to special warranty deeds for 235 acres and 205 acres of property with Odessa Industrial Development Corporation d/b/a Grow Odessa, eliminating most repurchase rights in exchange for a total payment of $4,347,500 ($1,000,000 cash and $3,347,500 promissory note due July 20, 2026, at 3.7% interest), securing property for development but adding short-term debt. On March 31, 2026, the Company issued 2,091,351 shares of common stock to SharonAI, Inc. as partial consideration under a January 16, 2026 Membership Interest Purchase Agreement, resulting in equity dilution.

• ·Promissory note allows prepayment at any time prior to maturity.
• ·Deed amendments retain limited repurchase right by Grow Odessa only if TCDC fails to begin Phase I construction within 2 years of recording.
• ·Shares issued under Section 4(a)(2) exemption from Securities Act registration.

31-03-2026

Lincoln National Corporation entered into a Third Amended and Restated Credit Agreement on March 27, 2026, with a syndicate of banks led by Bank of America, N.A., providing unsecured borrowing and letter of credit capacity of up to $2.0 billion maturing on March 27, 2031. The agreement replaces the prior facility dated December 21, 2023, and includes fees of 1.0% per annum on syndicated letters of credit and 0.125% per annum facility fee, both adjustable with credit ratings changes, along with financial covenants such as a minimum consolidated net worth of $9,932,000,000 plus 50% of post-December 31, 2025 equity proceeds, a debt-to-capital ratio not exceeding 0.35:1.00, and a 7.5% cap on certain non-operating indebtedness.

• ·Agreement contains customary covenants restricting liens, mergers/consolidations where LNC is not surviving entity, and dispositions of all/substantially all assets.
• ·Events of default include payment/covenant defaults, cross-defaults, bankruptcy, with termination rights and acceleration upon occurrence.
• ·Previous credit agreement dated December 21, 2023.

31-03-2026

Santander Holdings USA, Inc. (SHUSA), Santander Bank, National Association (SBNA), and Webster Bank, National Association (WBNA) entered into an Agreement and Plan of Merger dated March 30, 2026, providing for the contribution of WBNA shares to SBNA for no consideration followed immediately by the merger of WBNA into SBNA, with SBNA as the surviving Resulting Bank. This Bank Merger is an intermediate step contingent on prior transactions, including the acquisition of Webster Financial Corporation by Banco Santander, S.A. via HoldCo Transactions, Webster Virginia Contribution, and IHC Merger, all aimed at regulatory compliance and tax efficiency under Sections 332 or 368(a) of the Internal Revenue Code. The transaction requires OCC approval, with SBNA retaining its name, main office in Wilmington, DE, board composition including directors from both entities, and all assets/liabilities vesting in the Resulting Bank.

• ·Agreement approved unanimously by boards of SBNA, SHUSA, and WBNA.
• ·Resulting Bank main office: 824 N. Market Street, Suite 100, Wilmington, DE 19801.
• ·WBNA main office: 1959 Summer Street, Stamford, CT 06905.
• ·Effective Time not earlier than effective time of HoldCo Transactions.
• ·WBNA capital stock shares cancelled with no consideration.
• ·Resulting Bank board to include John R. Ciulla, Luis Massiani, and two WBS directors.
• ·Transaction Agreement for HoldCo Transactions dated February 3, 2026.

31-03-2026

Ameresco, Inc. (NYSE: AMRC) announced strategic executive appointments effective April 1, 2026, naming Nicole Bulgarino and Lou Maltezos as Co-Presidents to lead data centers, large energy projects, Federal Solutions, non-Federal projects, Smart Building Solutions, and Ameresco Canada, while George Sakellaris continues as CEO and Chairman. Peter Christakis was appointed COO to enhance project execution, risk management, procurement, health & safety, U.S. solar and battery operations, and European operations. These changes aim to strengthen operational alignment, accelerate growth, and reinforce 'One Ameresco' principles.

• ·Founded in 2000
• ·Headquartered in Framingham, MA
• ·Provides services to Federal, state and local governments, utilities, data centers, educational and healthcare institutions, housing authorities, and commercial and industrial customers

31-03-2026

Eli Lilly and Company (NYSE: LLY) announced a definitive agreement to acquire Centessa Pharmaceuticals plc (Nasdaq: CNTA) for $38.00 in cash per share plus a non-transferable CVR worth up to $9.00 per share (total potential $47.00), representing an aggregate upfront equity value of approximately $6.3 billion and potential CVR value of $1.5 billion, a 40.5% premium to Centessa's 30-day VWAP ending March 30, 2026. The deal expands Lilly's neuroscience portfolio into sleep-wake disorders via Centessa's OX2R agonist pipeline, led by cleminorexton (formerly ORX750). The transaction is expected to close in Q3 2026, subject to shareholder approval, court sanction, and regulatory clearances, with voting commitments from shareholders holding 24.1% of shares.

• ·CVR payments contingent on FDA approvals for narcolepsy type 2 ($2.00, prior to 5th anniversary of closing), idiopathic hypersomnia ($5.00, prior to 5th anniversary of closing), and first approval for any indication prior to January 1, 2030 ($2.00).
• ·Transaction via scheme of arrangement under England and Wales laws; UK Takeover Code does not apply.
• ·Advisors: Morgan Stanley & Co. LLC and Kirkland & Ellis LLP (Lilly); Centerview Partners LLC, Jefferies LLC, and Goodwin Procter LLP (Centessa).

31-03-2026

Snail, Inc. received a Nasdaq deficiency letter on March 26, 2026, notifying non-compliance with the $500,000 net income requirement and alternatives of $35M market value of listed securities or $2.5M stockholders' equity, based on net income in 2024 but losses in 2023 and 2025. The company has 45 days until May 11, 2026, to submit a compliance plan, potentially granting up to 180 days extension if accepted, though success is uncertain. Class A Common Stock continues trading on Nasdaq Capital Market pending compliance with other rules.

• ·Reported net income from continuing operations in 2024 but net losses in 2023 and 2025.
• ·Emerging growth company status.
• ·Potential options to regain compliance include equity/debt financing or similar transactions.

31-03-2026

On March 30, 2026, XMax Inc. entered into a Securities Purchase Agreement with StratoCore Solutions Ltd. to sell 1,958,000 shares of common stock at $3.575 per share, generating gross proceeds of $6,999,850 in a Regulation S private placement. While this provides the company with capital, the issuance is dilutive to existing shareholders as it increases the share count significantly.

• ·Private placement exempt from registration under Regulation S.
• ·Securities Purchase Agreement filed as Exhibit 10.1.
• ·Filing date: March 31, 2026; Earliest event date: March 30, 2026.

31-03-2026

Zenas BioPharma, Inc. completed a $200,000,000 aggregate principal amount public offering of 2.50% Convertible Senior Notes due 2032, generating net proceeds of approximately $193.7 million, with underwriters' option for an additional $30.0 million. Concurrently, the company closed an equity offering of 5,000,000 shares of common stock at $20.00 per share, yielding net proceeds of approximately $93.7 million, with an option for 750,000 additional shares. Net proceeds from both offerings, totaling about $287.4 million, will fund the planned U.S. commercial launch of obexelimab for IgG4-RD (if approved), orelabrutinib Phase 3 trials for progressive multiple sclerosis, ZB021 Phase 1/2 development, and general corporate purposes.

• ·Notes mature on April 1, 2032; interest payable semiannually starting October 1, 2026.
• ·Initial conversion rate: 37.7358 shares per $1,000 principal (approx. $26.50 conversion price); maximum 50.0000 shares per $1,000.
• ·Convertible upon specific conditions including stock price >130% of conversion price, low trading price, corporate events, redemption call, or from January 1, 2032.
• ·Redemption eligible after April 8, 2030 if stock price condition met.
• ·Fundamental Change repurchase right at principal plus accrued interest.
• ·Events of Default include payment defaults, covenant breaches, $30M indebtedness defaults, $30M judgments, bankruptcy.
• ·Offerings pursuant to shelf registration File No. 333-290777 filed October 8, 2025; agreements dated March 26, 2026; closed March 31, 2026.

31-03-2026

Modular Medical, Inc. amended its Certificate of Incorporation via a filing with the Nevada Secretary of State, effective as of the start of trading on March 31, 2026, to implement a 1-for-30 reverse stock split of its common stock. The amendment was approved by stockholders representing 65.14% of the voting power. No fractional shares will be issued, with cash provided in lieu to affected holders.

• ·Nevada entity ID: NV19981361748
• ·Amendment filed pursuant to NRS 78.385 and 78.390 (after issuance of stock)
• ·Certificate filed on March 30, 2026, with 8-K on March 31, 2026

31-03-2026

Vontier Corporation entered into a 364-day term loan agreement dated March 31, 2026, with PNC Bank, National Association as administrative agent and PNC Capital Markets LLC as lead arranger and bookrunner, providing a term loan credit facility to the borrower. Interest rates are determined by the Applicable Rate based on the borrower's debt ratings from S&P, Fitch, or Moody's, with Pricing Level 3 (0.950% for Term SOFR Loans, 0.000% for Base Rate Loans) applicable as of the closing date. This new facility is separate from the borrower's existing Second Amended and Restated Credit Agreement dated February 12, 2025, with Bank of America, N.A.

• ·Deal CUSIP: 92887YAP5; Term Loan CUSIP: 92887YAQ3
• ·Applicable Rate changes effective upon public announcement of Debt Rating changes
• ·Pricing Level determination rules: intermediate level if ratings differ by one level; higher of two if split by one; one level below higher if split by more than one

31-03-2026

Datacentrex, Inc. (Nasdaq: DTCX) announced the commencement of a proposed public offering of shares of its common stock and pre-funded warrants to certain investors, with net proceeds intended for working capital and general corporate purposes. The offering is subject to market conditions with no assurance on completion, size, or terms, and Dominari Securities LLC is acting as the sole placement agent. The company operates Scrypt compute assets and evaluates strategic transactions in asset-backed businesses.

• ·Shelf registration statement on Form S-3 (No. 333-286951), effective May 30, 2025.
• ·Press release dated March 26, 2026; SEC filing dated March 31, 2026.
• ·Investor contact: ir@datacentrex.com, 800-403-6150.

31-03-2026

The Cheesecake Factory Incorporated (CAKE) filed an 8-K on March 31, 2026, disclosing under Item 1.01 its entry into a material definitive agreement dated March 26, 2026. Item 2.03 incorporates this by reference, indicating the creation of a direct financial obligation or off-balance sheet arrangement. Details are qualified by reference to the exhibit terms, with no specific financial amounts or terms provided in the filing body.

• ·Filing covers period ending March 31, 2026
• ·Event dated 2026-03-26

31-03-2026

Affinity Bancshares, Inc. disclosed a Support Agreement dated March 30, 2026, executed by certain stockholders with Fidelity BancShares (N.C.), Inc. and The Fidelity Bank, committing to vote their Covered Shares (Sole Voting Shares and Shared Voting Shares) in favor of the Merger Agreement, under which Affinity and its subsidiary Affinity Bank will be acquired by Fidelity for cash consideration. The agreement includes restrictions on transfers, prohibitions on supporting alternative acquisition proposals, and cooperation covenants to facilitate the merger, effective until the stockholder meeting adjournment or Merger Agreement termination.

• ·Agreement terminates upon consummation of the Merger, termination of the Merger Agreement, or third anniversary of March 30, 2026.
• ·Does not apply to Fiduciary Shares held in trustee, guardian, custodian, executor, or similar capacities.
• ·Governed by North Carolina law.

31-03-2026

Ralliant Corp entered into Amendment No. 2 and Limited Consent to its Credit Agreement dated May 15, 2025, refinancing the existing Eighteen Month Term Loan Facility with a new three-year 2026 Term Loan facility of $550,000,000. The amendment includes consent to prepayment in full of Eighteen Month Term Loans, partial prepayment of Three-Year Term Loans, and payment in full to Departing Lenders, with facility adjustments among continuing Lenders. Effectiveness is subject to conditions including executed documents, legal opinions, certifications of no Material Adverse Effect since December 31, 2025, and payment of fees.

• ·Amendment dated March 30, 2026; Filing Date March 31, 2026
• ·Existing Credit Agreement dated May 15, 2025
• ·Reference to fiscal year ended December 31, 2025 for Consolidated Net Leverage Ratio on Pro Forma Basis
• ·Counsel: Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P.

31-03-2026

Biogen Inc. and its wholly-owned subsidiary, Aspen Purchaser Sub, Inc., entered into a Tender and Support Agreement dated March 31, 2026, with certain stockholders of Apellis Pharmaceuticals, Inc., concurrent with a Merger Agreement providing for a tender offer to acquire all outstanding shares of Apellis followed by a merger. The stockholders, beneficial owners of specified Subject Shares, agree to tender their shares into the offer promptly after commencement and not withdraw them, supporting the transaction as a condition to Biogen's willingness to proceed. No financial terms such as offer price are disclosed in the agreement.

• ·Agreement filed as Exhibit 99.1 in 8-K dated March 31, 2026, covering Items 1.01, 5.02, 8.01, 9.01.
• ·Stockholders represent ownership of Subject Shares as listed on Schedule I (not provided in excerpt).
• ·Tender must occur within 10 Business Days of Offer commencement or 5 Business Days of receiving Offer Documents.

31-03-2026

Texas Blocker Corp. entered into a Securities Contribution Agreement with investors to issue common shares in exchange for native tokens of the Zero Gravity (0G) blockchain, structured as a tax-deferred contribution under Section 351(a) of the Internal Revenue Code. The shares are to be exchanged for Consideration Shares under a separate Exchange Agreement immediately after closing. The transaction relies on exemptions under Section 4(a)(2) of the 1933 Act, Rule 506(b), and Regulation S, with closing subject to standard conditions including representations, warranties, and no Material Adverse Effect.

• ·Agreement dated as of [•], 2026; Closing Date to be mutually agreed upon.
• ·Filed under SEC 8-K Items 1.01 (Material Definitive Agreement), 1.02, 3.02 (Unregistered Sales of Equity Securities), and 9.01.
• ·Intended Tax Treatment per Revenue Ruling 2003-51.

31-03-2026

Biogen Inc. (Parent), via its wholly owned subsidiary Aspen Purchaser Sub, Inc. (Purchaser), entered into a Tender and Support Agreement dated March 31, 2026, with certain stockholders of Apellis Pharmaceuticals, Inc., requiring them to tender their Subject Shares in the forthcoming tender offer. This agreement is contemporaneous with a Merger Agreement under which Purchaser will commence an offer for all outstanding shares of Apellis common stock, followed by a merger with Apellis surviving as a Biogen subsidiary. No financial terms such as offer price or share counts were specified in the filing.

• ·Stockholders must tender Subject Shares no later than 10 Business Days after Offer commencement (or 5 Business Days after receipt of Offer Documents).
• ·Applies to Shares listed on Schedule I (not provided in filing).
• ·Tendered shares non-withdrawable unless agreement terminated.

31-03-2026

On March 27, 2026, Hendricks Tanker Company LLC, an indirect wholly-owned subsidiary of International Seaways, Inc., entered into a joinder agreement to the existing $500 Million Revolving Credit Facility (RCF), originally dated May 22, 2022. The subsidiary became a guarantor and pledged a VLCC tanker as collateral, serving as a Substitution Vessel to replace previously sold or released assets in the facility's collateral pool. No changes to the facility's terms or financial performance metrics were disclosed.

• ·Credit Agreement amendments: First Amendment dated March 10, 2023; Second Amendment dated April 26, 2024; Third Amendment dated October 7, 2025.
• ·Joinder Agreement filed as Exhibit 10.1.

31-03-2026

DSS, Inc. entered into a securities purchase agreement on March 26, 2026, with related party Alset International Limited for a $2,450,000 loan, represented by a 3% interest-bearing convertible promissory note (convertible at $0.74/share, 5-year maturity) and warrants to purchase 16,554,055 shares at $0.93/share (5-year term). The transaction, under common control of Chairman Chan Heng Fai, was approved by the Board and Audit Committee with recused interested directors but remains subject to stockholder approval. No immediate financial impact is reported, highlighting potential dilution from conversion/exercise.

• ·Transaction closing subject to Company stockholder approval.
• ·Transaction Documents filed as Exhibits 10.1 (Warrant), 10.2 (SPA), 10.3 (Note).

31-03-2026

Alexander’s Inc. subsidiary 731 Office One LLC entered into the Tenth Amendment of Lease with Bloomberg L.P., providing a $56,808,900 rent abatement from April 1 to December 1, 2026, while reducing the tenant fund from $113,617,800 to $56,808,900; the lease for the entire 731 Lexington Avenue office condominium expires unchanged on February 8, 2040. Concurrently, a Loan Amendment established a $56,808,900 free rent reserve account (with ~$53.9M already held), where monthly funds cover debt service with excess disbursed to the Company, mitigating the abatement's cash flow impact.

• ·Original Loan Agreement dated September 30, 2024
• ·Lease expiration unchanged at February 8, 2040

31-03-2026

Fortress Credit Realty Income Trust filed its Sixth Amended and Restated Declaration of Trust on March 23, 2026, effective via 8-K on March 31, 2026, replacing the prior Fifth Amended and Restated Declaration and governing the Maryland statutory trust's operations as a REIT. The document outlines purposes, powers, principal office at c/o The Corporation Trust Incorporated in Lutherville-Timonium, Maryland, and extensive definitions including multiple classes of common shares (e.g., Class B, D, E, F-I, F-S, I, J-1 through J-5) with NAV-based conversion rates to Class I shares. No financial performance metrics or changes are disclosed.

• ·Trust formed June 4, 2024; prior amendments on June 14, July 31, August 29, November 18, and December 26, 2024
• ·Resident agent: The Corporation Trust Incorporated, 2405 York Road, Suite 201, Lutherville-Timonium, Maryland 21093-2264
• ·Adviser defined with 'Adviser Change of Control' triggers related to Fortress ownership

31-03-2026

Main Street Capital Corporation entered into an underwriting agreement on March 27, 2026, to issue an additional $200,000,000 aggregate principal amount of 6.95% notes due 2029, increasing the total outstanding to $550,000,000 from the prior $350,000,000. The offering closed on March 31, 2026, generating net proceeds of approximately $202.8 million, which the company intends to use to repay outstanding indebtedness, including under its credit facilities. The New Notes are fungible with the Existing 2029 Notes, unsecured, and rank equally with existing unsecured indebtedness.

• ·Notes mature on March 1, 2029; interest accrues from March 1, 2026, with first payment on September 1, 2026.
• ·Optional redemption prior to February 1, 2029 at make-whole price (Treasury Rate + 45 bps); thereafter at 100% of principal.
• ·Holders have right to require repurchase upon change of control repurchase event at 100% of principal.
• ·Indenture covenants include compliance with modified Section 18(a)(1)(A) asset coverage requirements of the Investment Company Act.

31-03-2026

GeoVax Labs, Inc. (Nasdaq: GOVX) entered into a warrant inducement agreement with existing institutional investors for the immediate exercise of existing warrants to purchase 634,658 shares of common stock at $1.36 per share, generating gross cash proceeds of approximately $863,000 before fees, to be used for working capital and general corporate purposes. In exchange, investors will receive new unregistered warrants to purchase up to 1,269,316 shares at the same $1.36 exercise price, exercisable upon shareholder approval and expiring five years thereafter. The transaction is expected to close on or about April 1, 2026, under exemptions from Securities Act registration.

• ·New warrants exercisable starting on shareholder approval date and expire five years following that date
• ·Transaction relies on Section 4(a)(2) of the Securities Act and Regulation D exemption
• ·Filing date: March 31, 2026; expected closing: on or about April 1, 2026

31-03-2026

D.R. Horton, Inc. entered Amendment No. 13 to its Credit Agreement on March 27, 2026, establishing new Series D Revolving Credit Commitments of $1,012,500,000 (3-year term) and Series E Revolving Credit Commitments of $2,017,500,000 (5-year term), while increasing the aggregate Revolving Credit Commitment to $3,295,000,000 via additional commitments from 14 Increasing Lenders totaling approximately $540 million. The amendment also facilitates a commitment assignment from Comerica Bank to Fifth Third Bank and extends certain existing commitments to the fifth anniversary of the Amendment Effective Date. No defaults, events of default, or negative financial indicators were reported, with all representations and warranties reaffirmed.

• ·Increasing Lenders include Mizuho ($75M), PNC ($50M), Fifth Third ($50M), Regions ($25M), TCB ($25M), Huntington ($25M).
• ·Commitment Assignment: Comerica Bank assigns Series A Revolving Credit Commitment to Fifth Third Bank effective immediately prior to Amendment Effective Date.
• ·Lead Arrangers: Mizuho Bank, Ltd., BofA Securities, Inc., JPMorgan Chase Bank, N.A., TD Securities (USA) LLC, Truist Securities, Inc., U.S. Bank National Association, Wells Fargo Securities, LLC.
• ·Conditions to effectiveness include board resolutions, officer certificates, legal opinions, and payment of upfront fees to lenders with Amendment No. 13 Commitments.

31-03-2026

On March 31, 2026, Kayne Anderson BDC, Inc. entered into equity distribution agreements with KA Credit Advisers, LLC and sales agents including Truist Securities, Inc., RBC Capital Markets, LLC, Keefe, Bruyette & Woods, Inc., Regions Securities LLC, and UBS Securities LLC, enabling the potential issuance and sale of up to $150,000,000 in common stock. Sales will be at-the-market or negotiated transactions at prices not less than the net asset value per share, with sales agents receiving up to 1.5% commission, potentially covered by the adviser. The company has no obligation to sell any shares and may suspend the offering at any time.

• ·Sales of shares pursuant to prospectus supplement dated March 31, 2026, under shelf registration statement on Form N-2 (File No. 333-294788).
• ·Adviser may pay commissions or supplemental payments to ensure sales price not less than NAV, without reimbursement by the company.
• ·Opinion of Paul Hastings LLP on legality of share issuance attached as Exhibit 5.1.

31-03-2026

Cintas Corporation No. 2 entered into a Credit Agreement dated March 27, 2026, with KeyBank National Association as Administrative Agent, Swing Line Lender, and Issuing Lender, and other lenders including Fifth Third Bank, Morgan Stanley Bank, PNC Bank, U.S. Bank, and Wells Fargo Bank as arrangers and co-syndication agents. The agreement provides for revolving credit commitments and includes specific conditions for Bruin Acquisition Loans. No commitment amounts or financial performance metrics are specified in the filing excerpt.

• ·Published Transaction CUSIP Number: 17259CAL9
• ·Published Revolver CUSIP Number: 17259CAM7
• ·SEC 8-K filed March 31, 2026, covering Items 1.01, 1.02, 2.03, 9.01

31-03-2026

Caring Brands, Inc., a Nevada corporation, filed an 8-K on March 31, 2026, attaching Exhibit 3.1: Amendment No. 1 to its Bylaws, effective March 29, 2026. The amendment replaces Section 2.06, reducing the quorum requirement for annual or special shareholder meetings to 33 1/3% of outstanding capital stock entitled to vote, with provisions for adjournment without notice and continuation if at least 1/3 of shares remain represented. All other bylaws remain unchanged.

• ·Filing Items: 3.03, 5.02, 5.03, 9.01

31-03-2026

Purple Innovation reported fourth quarter 2025 net revenue of $140.7 million, up 9.1% YoY driven by wholesale growth from Mattress Firm and Costco partnerships, though offset by e-commerce declines, with Adjusted EBITDA of $8.8 million and gross margin of 41.9%. Full year 2025 net revenue declined 3.9% to $468.7 million due to e-commerce headwinds, but Adjusted EBITDA improved to a positive $1.9 million from $(20.8) million, supported by gross margin expansion to 40.2% and 15.3% lower operating expenses. The company expects 2026 full year revenue of $500-520 million and Adjusted EBITDA of $20-30 million, with Q1 Adjusted EBITDA loss of $(7)-(4) million.

• ·Q4 GAAP net loss of $3.2 million, improved from $8.5 million in Q4 2024.
• ·Full year GAAP net loss of $51.4 million, improved from $97.9 million in 2024.
• ·Inventories up 5.0% YoY to $59.7 million as of Dec 31, 2025.
• ·Q1 2026 revenue outlook $100-105 million; Adjusted EBITDA $(7)-(4) million.

31-03-2026

IO Biotech, Inc. ceased operations and filed a voluntary Chapter 7 bankruptcy petition on March 31, 2026, in the United States Bankruptcy Court for the District of Delaware, leading to appointment of a trustee to liquidate assets and pay claims per Bankruptcy Code priorities. All board directors resigned, all employees and officers including CEO Mai-Britt Zocca and CFO Amy Sullivan were terminated, and the filing triggers default on a €22.5 million loan from the European Investment Bank, with stays possible under Bankruptcy Code. Shareholders are unlikely to receive any distribution, and the company will not file its 10-K for fiscal year ended December 31, 2025.

• ·Bankruptcy filed under Chapter 7 of Title 11 of the United States Code.
• ·Trading in common stock (IOBT on Nasdaq) is highly speculative with substantial risk of total loss.
• ·Audit of FY 2025 financial statements incomplete; no further SEC periodic reports will be filed.

31-03-2026

ImmunityBio secured $75 million in non-dilutive financing under its existing Revenue Interest Purchase Agreement (RIPA) with Oberland Capital, increasing total committed capital to $375 million, while Nant Capital converted $25 million of a $505 million promissory note into 4.6 million shares of common stock. These transactions strengthen the balance sheet to support global expansion following ANKTIVA approvals across five jurisdictions covering 34 countries since April 2024. No declines or flat metrics were reported.

• ·ANKTIVA approvals: US (FDA, April 2024), UK (MHRA, July 2025), Saudi Arabia (SFDA, January 2026 for NMIBC CIS and NSCLC), EU (February 2026 covering 27 member states plus Iceland, Norway, Liechtenstein), Macau SAR (March 2026)
• ·Global regulatory footprint of 34 countries established in under two years from initial US FDA approval

31-03-2026

SmartKem, Inc. adopted a Certificate of Designations on March 27, 2026, creating 31,412 shares of Series A Convertible Preferred Stock with a par value of $0.0001 per share, certified by CFO Barbra Keck. The preferred shares rank senior to common stock regarding dividends and liquidation preferences, are convertible into common stock at a conversion price of $0.5812, and accrue default dividends at 15.0% per annum upon a Triggering Event. This series is to be issued pursuant to a Securities Purchase Agreement.

• ·Preferred shares rank junior to any Senior Preferred Stock and on parity with Parity Stock.
• ·Board resolution adopted pursuant to DGCL Section 151(g) and company Certificate of Incorporation.
• ·Filing date: March 31, 2026; covers 8-K Items 1.01, 3.02, 5.03, 8.01, 9.01.

31-03-2026

CoreWeave, Inc. (Nasdaq: CRWV) closed an $8.5 billion delayed draw term loan facility (DDTL 4.0 Facility), the first investment-grade rated (A3 by Moody’s, A(low) by DBRS) GPU-backed financing secured by HPC infrastructure and a customer contract. The facility allows initial borrowing of up to $7.5 billion, expandable to $8.5 billion, at rates of SOFR + 2.25% (floating tranche) and approximately 5.9% (fixed tranche), maturing in March 2032, reflecting reduced cost of capital and building on $28 billion in equity and debt commitments over the past 12 months. The oversubscribed transaction was co-structured by MUFG and Morgan Stanley, with Goldman Sachs and JPMorgan as lead arrangers, anchored by Blackstone Credit & Insurance.

• ·Facility secured by substantially all assets of CoreWeave Compute Acquisition Co. VIII, LLC
• ·CoreWeave established in 2017 and completed public listing on Nasdaq (CRWV) in March 2025

31-03-2026

USBC, Inc. received a letter from NYSE American LLC on March 27, 2026, confirming it has regained compliance with all continued listing standards in Part 10 of the NYSE American Company Guide, resolving prior stockholders’ equity deficiencies noted on September 27, 2024. The company is no longer subject to the compliance plan, the '.BC' indicator will be removed, and it will be taken off the noncompliant issuers list. A press release announcing this was issued on March 31, 2026.

• ·Compliance plan accepted by NYSE American on December 10, 2024.
• ·Company subject to ongoing monitoring; failure to maintain compliance within 12 months under Section 1009(h) could lead to review and potential accelerated delisting.